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MRI‑derived radiomics model 
for baseline prediction of prostate 
cancer progression on active 
surveillance
Nikita Sushentsev1,8*, Leonardo Rundo1,2,8, Oleg Blyuss3,4,5, Vincent J. Gnanapragasam6,7, 
Evis Sala1,2 & Tristan Barrett1
Nearly half of patients with prostate cancer (PCa) harbour low‑ or intermediate‑risk disease considered 
suitable for active surveillance (AS). However, up to 44% of patients discontinue AS within the first 
five years, highlighting the unmet clinical need for robust baseline risk‑stratification tools that enable 
timely and accurate prediction of tumour progression. In this proof‑of‑concept study, we sought to 
investigate the added value of MRI‑derived radiomic features to standard‑of‑care clinical parameters 
for improving baseline prediction of PCa progression in AS patients. Tumour  T2‑weighted imaging 
(T2WI) and apparent diffusion coefficient radiomic features were extracted, with rigorous calibration 
and pre‑processing methods applied to select the most robust features for predictive modelling. 
Following leave‑one‑out cross‑validation, the addition of T2WI‑derived radiomic features to 
clinical variables alone improved the area under the ROC curve for predicting progression from 0.61 
(95% confidence interval [CI] 0.481–0.743) to 0.75 (95% CI 0.64–0.86). These exploratory findings 
demonstrate the potential benefit of MRI‑derived radiomics to add incremental benefit to clinical data 
only models in the baseline prediction of PCa progression on AS, paving the way for future multicentre 
studies validating the proposed model and evaluating its impact on clinical outcomes.
Prostate cancer (PCa) is the second commonest and the sixth deadliest male cancer worldwide, with its incidence 
expected to double by 2030 due to an ageing male  population1,2. In the UK, 43% of men present with low- and 
favourable intermediate-risk localised disease, for which level 1 evidence suggests non-inferiority of active sur-
veillance (AS) to radical treatment in terms of 10-year  survival3–7. However, the lack of consensus on both the 
stringency of inclusion criteria and the definition of disease progression have led to a significant variability of 
how AS protocols are run both across  centres8 and indeed across  guidelines9. As a result, a cumulative five-year 
dropout rate on AS reaches 44%, of which 27% are triggered by disease  progression10,11. This highlights the unmet 
clinical need for developing robust baseline risk-stratification tools enabling early detection of patients harbour-
ing lesions with a high potential for  progression12. These patients would either require stricter AS follow-up or 
should be considered for radical treatment.
Numerous studies recently summarised in a systematic review by Sierra et al.13 have investigated the utility of 
both nomograms and individual clinicopathological predictors of histopathological progression in AS cohorts. 
However, none of the investigated models has entered routine clinical practice due to their low predictive accu-
racy and poor performance with external validation. One possible explanation for this may be the intrinsic 
difficulty of standardising the predictors, with an obvious example being PSA density that varies considerably 
depending on the imaging modality used for measuring prostate  volume14. Furthermore, pathology results 
from needle biopsy may differ from the final pathology at prostatectomy due to sampling error, inter-observer 
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variation, borderline grades, or upgrading due to oversampling the most radiologically suspicious  area10. Con-
versely, the ability of MRI to visualise the whole tumour volume coupled with ongoing attempts to standardise 
image acquisition  parameters15 provide the potential to investigate the ability of quantitative image-derived 
features, or radiomics, to advance the development of accurate and reproducible predictors of disease progres-
sion on AS.
In PCa, a considerable body of radiomics research has focused on improving the detection of clinically 
significant  disease16–18 to address the moderate positive predictive value of qualitative mpMRI assessment and 
reduce the overdiagnosis of indolent  disease19,20. Zhang et al.21 recently introduced a radiomic model predicting 
histopathological upgrading of PCa from biopsy to radical prostatectomy, which may also improve baseline lesion 
characterisation. Furthermore, radiomics models have been developed to preoperatively predict the probability 
of extracapsular  extension22–24, which is essential for accurate local staging of the disease and subsequent clini-
cal decision-making. However, to the best of our knowledge, no attempts have been made to utilise radiomics 
for predicting disease progression in patients enrolled on AS programmes, the proportion of which is growing 
steadily in North America, Europe, and  Australia25.
Therefore, in this proof-of-concept study, we sought to develop a radiomics model that would predict the base-
line risk of PCa progression on AS. To achieve this, we extracted MRI-derived intratumoural radiomic features 
from AS patients with and without disease progression over a similar follow-up period. The predictive perfor-
mance of the resulting sequence-specific radiomic models was assessed both individually and in combination 
with a clinical predictive model consisting of standard-of-care baseline clinicopathological biomarkers, with the 
aim of identifying a combined model with the highest overall performance to inform the future work in the field.
Methods
Patient population. This retrospective case–control study was part of a service evaluation of the pros-
tate diagnostic pathway, with the need for informed consent for data analysis waived by the local institutional 
review board (NRES Committee East of England, UK). All experimental protocols of this study were carried 
out in accordance with the Declaration of Helsinki, as well as all the relevant guidelines and regulations, and 
were approved by the aforementioned local institutional review board. The study included patients with biopsy-
proven PCa visible on both  T2-weighted Imaging (T2WI) and apparent diffusion coefficient (ADC) maps, who 
were enrolled on active surveillance according to local  criteria26 and had a minimum follow-up of two years with 
at least two consecutive 3 T MRI scans performed on the same magnet. The exclusion criteria were patients on 
AS with no MR-visible lesion, undergoing any prior treatment for PCa or benign disease, or the presence of total 
hip replacement or other pelvic metalwork.
Patients were divided into two groups depending on disease progression status. Cases were represented by 
patients who demonstrated disease progression, which was defined as a switch to radical treatment triggered by 
either confirmed histopathological progression on repeat targeted biopsy, or definitive radiological stage progres-
sion of the target lesion (MRI-derived  PRECISE23 score 5). The control group included patients in whom the 
disease was regarded stable over the same follow-up period, with no signs of radiological progression recorded on 
all prospective MRI scans (PRECISE score 3) and no histopathological progression noted on all repeat targeted 
biopsies, with both criteria being compulsory.
Baseline clinicopathological predictors of disease progression. To investigate the predictive value 
of standard-of-care clinicopathological predictors of disease progression, the following baseline parameters were 
collected for all included patients: PSA, MRI-derived gland volume, PSA density, MRI-derived Likert score of 
tumour probability, target lesion localisation (peripheral zone or transition zone), and target lesion biopsy grade 
group.
Biopsy technique. Depending on clinical recommendation, biopsy was performed by either a transrec-
tal or transperineal approach, using MRI/ultrasound fusion. All biopsy procedures were performed by expe-
rienced urologists and included 12–24 systematic cores, with 2–4 separate target cores acquired from the MRI 
defined lesion/s. All targets were defined by radiologists pre-procedure using T2WI as the primary and diffu-
sion-weighted imaging as the secondary source images, using the DynaCAD system (InVivo Corp, Orlando, 
FL, USA) for transrectal and Biopsee software (Oncology Systems Limited, Shrewsbury, UK) for transperineal 
approaches as previously  described24.
MRI acquisition parameters. Patients underwent prostate MRI on a 3 T MR750 scanner (GE Healthcare, 
Waukesha, WI) using a 32-channel receiver coil. Intravenous injection of hyoscine butylbromide (Buscopan, 
20 mg/mL; Boehringer, Ingelheim am Rhein, Germany) was administered prior to imaging to reduce peristaltic 
movement, unless clinically contraindicated. Multiparametric MRI protocol included Axial  T1 and multipla-
nar high-resolution  T2-weighted 2D fast recovery FSE (field of view (FOV) 18 × 18  cm2; voxel size 0.35 × 0.35 
 mm2; slice thickness 3 mm; gap 0 mm). Diffusion-weighted imaging (DWI) was performed using a spin-echo 
echo-planar imaging pulse sequence (FOV 28 cm; slice thickness 3 mm; gap 0 mm; b-values: b-150, b-750, and 
b-1,400 s/mm2) and an additional small FOV (24 cm) b-2,000 s/mm2 DWI sequence; ADC maps were calcu-
lated automatically. Dynamic contrast enhancement was performed using a standard sequence (FOV 24 cm; 
slice thickness and gap 3 mm and 0 mm, respectively; temporal resolution 7 s) following a bolus of Gadobutrol 
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Image analysis and segmentation. The MR images were interpreted prospectively by one of four sub-
specialist uro-radiologists with 5–16 years’ experience of reporting prostate MRI, with each having read > 2,000 
cases to be considered  experts27,28. MRI sequences were evaluated based on the Prostate Imaging-Reporting 
and Data System (PI-RADS) structured scoring  criteria29. An overall impression was then used to derive a Lik-
ert suspicion score, wherein Likert 1 = clinically significant prostate cancer (csPCa) highly unlikely, 2 = csPCa 
unlikely, 3 = indeterminate for csPCa, 4 = csPCa likely, 5 = csPCa highly  likely30. The assigned Likert scores were 
subsequently reviewed by independent readers as part of multidisciplinary team meetings.
For texture analysis, tumour ROIs were drawn on anatomical T2WI (example ROIs are presented in Fig. 1) 
and ADC maps by a fellowship-trained uro-radiologist with 12 years’ experience of reporting prostate MRI (TB) 
and an imaging research fellow (NS). The segmentation was performed in consensus using the open-source 
segmentation software ITK-SNAP25. The reliability of image segmentation was evaluated by applying ROI mor-
phological opening and closing using the SciPy Python package.
Figure 1.  Comparison of T2-weighted images of the prostate obtained at baseline pre-biopsy (a–c) and 
follow-up (d–f) mpMRI scans from patients enrolled on active surveillance. Images (a,d) were obtained from 
a patient with stable 3 + 3 = 6 disease that showed neither radiological not histopathological progression over 
a follow-up period of three years. Images (b,e) were obtained from a patient with both radiological (PRECISE 
4) and histopathological (3 + 4 = 7 to 4 + 3 = 7) progression. Images (c,f) were obtained from a patient with 
confirmed histopathological progression (3 + 3 = 6 to 3 + 4 = 7) but radiologically stable disease (PRECISE 3). 
The best-performing predictive model (T2WI-derived radiomic features, PSA and PSA density) predicted the 
clinical outcome in all three presented cases.
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Radiomics analysis. Figure 2 illustrates the overall workflow of the radiomics pipeline utilised to develop 
and validate predictive models for PCa progression on AS. The key stages of the pipeline are described in the 
following sections.
Radiomic feature extraction. The analysed features were extracted using  PyRadiomics31, which is an 
open-source Python package developed for the standardisation of radiomic feature  extraction32. We used PyRa-
diomics version 2.0 and Python 3.7.5. Six feature classes were extracted: (1) first-order intensity histogram statis-
tics, (2) Grey Level Co-occurrence Matrix features (GLCM)33,34, (3) Grey Level Run Length Matrix (GLRLM)35, 
(4) Grey Level Size Zone Matrix (GLSZM)36, (5) Grey Level Dependence Matrix (GLDM)37, and (6) Neighbour-
ing Gray Tone Difference Matrix (NGTDM)38. All extracted features are listed in Supplementary Table S1.
3D feature computation without any resampling was used to avoid interpolation artifacts. According to the 
Initiative for Biomarker Standardization Initiative (IBSI)32, the use of the number of bins is favoured over the 
bin width in the case of arbitrary intensity units, such as MRI. For the same motivation, no resegmentation (i.e. 
the voxels outside a specified range are removed from the mask prior to texture feature calculation) was applied. 
More details are available in the Supplementary Methods.
Calibration and pre‑processing. We aimed at reducing the initial set of extracted features by a subset of 
features that are both robust against ROI perturbations and independent from the MRI acquisition parameters.
Firstly, with the goal of identifying the robust features, we perturbed the original prostate cancer ROIs by using 
morphological operators (opening and closing with a 3D spherical structuring element of 1-pixel radius)39. By so 
doing, we produced three versions for each ROI (namely, original, opening and closing). This procedure simu-
lates the variability of the ROIs, by considering intra- and inter-reader dependence during manual  contouring40. 
Starting from these three sets of ROIs, the radiomic features were extracted separately for T2WI and ADC by 
using different quantisation configurations: the number of bins varied in {8, 16, 32, 64, 128, 256}. Thus, the two 
perturbations applied to the original ROIs and the different quantization settings yielded 18 configurations of 
radiomic features. Therefore, the ROI perturbations were aimed at assessing the most robust quantisation set-
ting (i.e. rebinning).
The ICC was considered to determine the most robust features against the ROI perturbations whilst the num-
ber of bins varied  too41. ICC analysis was applied to these 18 configurations of features to establish the number 
of bins that achieved the largest set of robust features for T2WI and ADC separately. In particular, we considered 
the two-way random-effects model (or mixed-effects), consistency, single rater/measurement, ICC(3,1)42:
where MSR , MSE and MSC are the mean square for rows, mean square for error and mean square for columns, 
respectively.
The chosen number of bins represents the most reliable quantisation configuration (i.e. rebinning) according 
to the ROI perturbations via morphological operators. A cut-off value of 0.8 was used for the ICC to identify 
the number of features with high robustness. The used quantisation configuration was selected accordingly, by 
considering the number of bins that obtained the highest number of robust features for both T2w and ADC. The 
highly robust features with ICC > 0.8 were then used in the downstream pre-processing phases. ICC > 0.9 is the 
setting used for ‘excellent robustness’, however, in our predictive radiomics analysis we chose the less aggressive 
cut-off ICC > 0.8 as a measure for ‘high robustness’, representing a compromise between ICC > 0.9 and ‘high or 
moderate robustness’ (ICC > 0.5)41,43.
Secondly, the extracted features might be affected by the MRI acquisition characteristics, such as scanner 
type, scanner settings, imaging protocols and acquisition  parameters44. In particular, we calculated the Spearman 
(1)ICC(3, 1) =
MSR − MSE
MSR + (k − 1)MSE
,
Figure 2.  Overall workflow of the radiomics pipeline used in this study. The main phases are: (i) calibration, (ii) 
pre-processing, and (iii) predictive modelling with leave-one-out cross validation (LOOCV), for which a colour 
legend is shown in the bottom right corner.
5
Vol.:(0123456789)
Scientific Reports |        (2021) 11:12917  | https://doi.org/10.1038/s41598-021-92341-6
www.nature.com/scientificreports/
correlation coefficient for each radiomic feature against each considered MRI acquisition parameter, namely: 
(i) echo time (TE); (ii) repetition time (TR); (iii) flip angle; (iv) slice thickness; (v) spacing between slices; (vi) 
pixel spacing. A test–retest analysis for assessing feature robustness was not performed given that clinical MRI 
scans were  used32. Our aim was to decouple possible dependencies between each feature and the principal MRI 
acquisition parameters in our highly homogeneous dataset, thus, this pre-processing step was based just on a 
simple Spearman’s correlation.
Feature selection and predictive modelling. In order to accommodate the high-dimensional nature 
of radiomics, minimise potential model overfitting, and reduce the dimensionality, we used six feature selection 
approaches including Fisher Score (FSCR), T-Score (TSCR), Wilcoxon Score (WLCX), Gini index (Gini), Multi-
variate Mutual Information Maximization (MIM), and Minimum Redundancy Maximum Relevance (MRMR). 
In this proof-of-concept study, we did not intend to build a single best-performing model—instead, we aimed 
to investigate whether the radiomic features were complementary to clinical features. Therefore, we limited the 
total number of features selected by commonly applied cut-offs. Given the low number of available clinical fea-
tures, we used the top 5 features from each approach, whereas for each radiological dataset, the total number of 
features was restricted to 10, leading us to incrementally use the top 15 features for each combination.
Following the identification of the optimal number of features, several machine learning techniques were 
developed to incorporate these features into a binary classifier for distinguishing patients with the disease pro-
gression from those who remained stable over the study period. Methods used included k-nearest neighbours 
(KNN), logistic regression (LG), linear discrimination analysis (LDA), general linear model (GLMnet), support 
vector machine (SVM) and random forest (RF), with the analysis settings set as default. Given a limited sample 
size of the data, a leave-one-out cross-validation (LOOCV) scheme was used in order to further minimise the 
risk of overfitting. In brief, to investigate the predictive ability of clinical and radiomic features, every machine 
learning approach was trained using data from all the patients but one, with all the hyperparameters tuned and 
then applied to the remaining patient. The default set of hyperparameters was used, including k and λ in the KNN 
and GMLnet methods, respectively, which were tuned independently at each step of the LOOCV procedure. This 
approach enabled us to demonstrate the overall predictive ability of the analysed dataset rather than developing 
one best-performing model. Given the exploratory design, we did not plot the receiver operating characteristic 
(ROC) curves as they would be based on a LOOCV scheme that implies constructing and evaluating a number 
of models (as many as the number of patients included) rather than a single model.
Statistical and computational analysis. Along with the PyRadiomics-based feature extraction, the pre-
processing and calibration steps in the radiomic pipeline were performed using the MatLab® R2019b (64-bit 
version) environment (The MathWorks, Natick, MA, USA), whilst the feature selection and predictive modelling 
were performed in R 4.0.2 using the praznik, MXM, and caret packages.
Results
Patient characteristics. This case–control study included 71 patients followed-up on the AS programme 
in our centre between May 2013 and April 2020. 73 MR-visible lesions were included in the analysis, of which 
35 showed confirmed disease progression (histopathological = 25; radiological = 10) and 38 remained stable over 
the study period; sample cases representing the two groups are presented in Fig. 1. 12/73 (16%), 29/73 (40%), 
and 32/73 (44%) of lesions harboured Likert scores 3, 4, and 5, respectively. The mean age of the study popula-
tion was 65.3 ± 6.4 years, with no inter-group difference observed between the progressors and non-progres-
sors (66.4 ± 6.1 years vs 64.2 ± 6.5 years, respectively; p = 0.099). The mean follow-up length in this study was 
4.4 ± 2.2 years for non-progressors. The mean time to progression period for progressors was 4.1 ± 2.2 years vs 
4.8 ± 2.9 years of follow-up for non-progressors (p = 0.107). Table 1 presents the inter-group comparison of the 
baseline clinicopathological predictors of the disease progression, with PSA and PSA density being significantly 
higher in progressors compared to non-progressors (p = 0.021 and 0.003, respectively).
Table 1.  Intergroup comparison of standard-of-care baseline clinicopathological predictors of prostate cancer 
progression in patients enrolled on active surveillance.
Baseline predictor
Progressors (n = 34) Non-progressors (n = 37)
p-valueMedian (IQR)
PSA, ng/mL 7.0 (4.9–8.7) 4.9 (3.4–6.8) 0.021
Gland-volume, mL 45.0 (32.0–53.0) 44.8 (35.8–66.5) 0.329
PSA density 0.17 (0.10–0.22) 0.09 (0.06–0.15) 0.003
Likert score 4.0 (4.0–5.0) 4.0 (4.0–5.0) 0.532
Biopsy grade group 1 (3 + 3 = 6) 26 28
–
Biopsy grade group 2 (3 + 4 = 7) 8 10
Target lesion in the peripheral zone 23 29
–
Target lesion in the transition zone 12 9
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Radiomics analysis: calibration and pre‑processing. Since the choice of the quantisation, or rebin-
ning, is critical, we performed the robustness analysis based on the Intraclass Correlation Coefficient (ICC) com-
puted on the features extracted from the original regions-of-interest (ROIs) and their perturbations using mor-
phological operations (see “Methods”). The number of bins varied in {8, 16, 32, 64, 128, 256}, and the number 
of high robust features was identified by an ICC > 0.8. For a homogenous setting suitable for both  T2-weighted 
imaging (T2WI) and apparent diffusion coefficient (ADC), we took into account the sum of the highly robust 
features for both sequences. Table 2 shows that 128 bins provided the most suitable quantisation configuration 
for T2w and ADC. Therefore, out of 107 features extracted by PyRadiomics, at 128 bins, the number of highly 
robust features was 34 and 59 for T2WI and ADC, respectively. The dependence analysis between the result-
ing radiomic features and MRI acquisition parameters—based on a Spearman correlation analysis—showed no 
interdependent features (p < 0.001), thus confirming the homogeneity of the analysed dataset in terms of MRI 
acquisition parameters.
Feature selection and predictive modelling. The areas under the ROC curve (AUCs) for clinicopatho-
logical predictors, T2WI-derived radiomic features and ADC-derived radiomic features alone, as well as for 
their combinations, are presented in Fig. 3, with 95% confidence intervals (CI) for each of the resulting models 
validated using LOOCV listed in Supplementary Tables S2-8. In order to account for the different numbers of 
clinical and radiomic features, we used the top 5 features for analysis of the clinical data, the top 10 features for 
each of the radiological data and top 15 features for combinations of these. Since GLMnet used a regularisation 
approach, there were two instances when the model shrunk to the intercept only and therefore was not reported 
(Supplementary Tables S3 and S8). The best predictive performance—AUC = 0.75 (95% CI 0.636–0.862)—was 
Table 2.  Number of features with high robustness (ICC > 0.8) by varying the number of bins in the 
quantisation step for radiomic feature extraction for T2w and ADC MR images separately.
Number of bins
Number of features with 
excellent robustness
T2WI ADC Combined
8 38 47 85
16 36 49 85
32 33 53 86
64 35 55 90
128 34 59 93
256 33 56 89
Figure 3.  Heatmaps summarizing areas under the ROC curve (AUC) of predictive models developed including 
(a) clinicopathological predictors alone, (b) T2WI-derived radiomic features alone, (c) ADC-derived radiomic 
features alone, (d) a combination of clinicopathological predictors, T2WI-, and ADC-derived radiomic features, 
(e) a combination of clinicopathological predictors and T2WI-derived radiomic features, (f) a combination 
clinicopathological predictors and ADC-derived radiomic features, and (g) a combination of T2WI- and 
ADC-derived radiomic features. Each cell presents an AUC for a model developed using a given combination of 
feature selection and machine learning algorithms. 95% confidence intervals for each model are summarised in 
Supplementary Tables S1-7, respectively. Blank cells (b,g) denote models shrunk to the intercept only due to the 
regularisation approach used by GLMnet.
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achieved for a model combining clinicopathological predictors with T2WI-derived radiomic features (Table 3) 
developed using the Wilcoxon signed rank test and k-nearest neighbours as feature selection and classification 
algorithms, respectively. Summary performance characteristics of the model based on sensitivity and specificity 
cut-offs are presented in Table 4. From a clinical standpoint, optimal performance is achieved with a combina-
tion of specificity 0.80 and sensitivity of 0.63. An intergroup comparison of the constituent features between 
progressors and non-progressors using the Wilcoxon rank sum test with Bonferroni correction revealed that 
only PSA-density was significantly different between the two groups (p = 0.03); Supplementary Fig. S1.
Discussion
This proof-of-concept study investigates the added value of MRI-derived radiomics to standard-of-care clin-
icopathological biomarkers for baseline prediction of PCa progression on active surveillance in patients with 
MR-visible lesions. The combined predictive model, incorporating PSA and PSA density (PSAD) with selected 
T2WI-derived radiomic features, showed improved performance compared to models utilising clinical data 
alone. These results suggest a role for MRI-derived radiomics as an additional risk-stratification tool to triage 
patients suitable for AS depending on the progressive potential of the target lesions.
The role of mpMRI in identifying patients suitable for AS has been expanding gradually over the recent years, 
primarily building on its high negative predictive value for the presence of clinically significant disease unsuit-
able for  AS45. Several studies have confirmed the ability of mpMRI to better identify men at risk of immediate 
reclassification at their initial  assessment46, also highlighting the fact that the presence of an MR-visible lesion 
at baseline is associated with higher risk of disease progression on  AS12,47–52. However, no systematic attempts 
other than in a diagnostic meta-analysis by Zhai et al.53 have been made to explore the ability mpMRI to further 
stratify MR-visible lesions based on their progressive potential in patients otherwise suitable for AS. Adding this 
extra risk-stratification element at baseline, which showed promise in other tumour types such as  bladder54 and 
 ovarian55 cancers, may improve clinical decision-making and help refine and personalise follow-up protocols. 
For these purposes, MRI-derived radiomics presents a promising approach due to its quantitative nature and 
the rapid development of novel machine learning algorithms for feature selection that may help overcome the 
known poor cross-system reproducibility of the  technique56,57.
Table 3.  Summary clinicopathological and T2WI-derived radiomic features comprising the best-performing 
predictive model of prostate cancer progression on active surveillance developed using the Wilcoxon signed 
rank test and k-nearest neighbours algorithms for feature selection and classification, respectively.










Grey level co-occurrence matrix (GLCM)
Informational measure of correlation 1
Informational measure of correlation 2
MCC: maximal correlation coefficient
Grey level run length matrix (GLRLM)
Grey level NonUniformity
Run length NonUniformity
Grey level size zone matrix (GLSZM) Grey level NonUniformity
Grey level dependence matrix (GLDM) Grey level NonUniformity
Neighbouring grey-tone difference matrix (NGTDM) Busyness
Table 4.  Summary performance characteristics of the best-performing model (T2WI-derived radiomic 
features, PSA, and PSA density) from the leave-one-out cross validation results presented in Table 3. 
Depending on the clinical need, the predictive performance can be adjusted by prioritising specificity over 
sensitivity and vice versa, with the resulting parameter combinations presented in the table.
Parameter Specificity Sensitivity Sensitivity Specificity
Combination
0.70 0.70 0.70 0.70
0.75 0.67 0.75 0.63
0.80 0.63 0.80 0.52
0.85 0.54 0.85 0.34
0.90 0.37 0.90 0.28
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In this study, only two clinicopathological predictors (PSA and PSAD) were included in the best-performing 
model. These results are in line with those of previous studies, in which baseline PSAD had a significant effect on 
mean progression-free survival time in patients on AS  programmes12,52,58,59. It should be noted that in our cohort, 
PSAD was largely determined by PSA rather than the gland volume, with the latter being broadly similar in both 
progressors and non-progressors, thereby explaining the inclusion of PSA in the best-performing model along-
side PSAD. Given the relative homogeneity of the AS cohort in our centre, the inclusion of MR-visible lesions 
only (Likert scores 3–5), and the case–control nature of the study, other clinicopathological predictors (Likert 
score, biopsy ISUP grade group, and zonal location of lesions) showed no intergroup difference, thereby provid-
ing a possible explanation for the observed moderate performance of clinicopathological predictive models.
Interestingly, a similarly moderate predictive performance was demonstrated by both standalone and com-
bined T2WI- and ADC-derived radiomic models. The moderate performance of ADC-derived radiomics may 
be explained by the intrinsically limited ability of ADC mapping to differentiate low- vs intermediate-risk disease 
using a clinical monoexponential-fit model, for which more advanced diffusion techniques such as diffusion 
kurtosis imaging (DKI) and Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumors (VER-
DICT) MRI have shown greater  promise60,61. A considerable increase in the predictive performance was, however, 
achieved by a model combining T2WI-derived radiomic features with PSA and PSAD, highlighting a synergy 
between radiomic and clinicopathological features for improving baseline detection of lesions with high progres-
sive potential. Of thirteen radiomic features included in the best-performing model, five were representative 
of the tumour shape, size, and volume, which aligns well with the results of previous studies suggesting a link 
between baseline MRI-derived lesion size and the disease progression on  AS52. In terms of the model performance 
characteristics, the achieved specificity and sensitivity of 0.80 and 0.63 could be employed to focus its clinical use 
on identifying patients at low risk of progression who may benefit from less stringent AS protocols, maximising 
specificity whilst not being overly restrictive on patient uptake of AS. In addition to providing an evidence base 
for avoiding unnecessary biopsies, similar models might increase confidence of both patients and clinicians in 
the AS protocol chosen based on the low overall prostate cancer-specific mortality in AS cohorts even in patients 
with unfavourable intermediate-risk  disease62.
This study has several limitations. Data were collected from a single centre, and additional external validation 
of the proposed model is required. This was, however, mitigated by the rigorous patient selection and matching, 
calibration, and pre-processing stages aimed at reducing overfitting and maximising the reliability of subsequent 
predictive modelling and cross-validation steps. Only patients with MR-visible lesions were included in the 
analysis, limiting generalisability of the findings, given that only 50% of patients included on AS programmes 
will have an MRI lesion  detected52,63. The choice of such a cohort was, however, deliberate given that the presence 
of MR-visible lesions is in itself a poor prognosticator of PCa progression on AS, thereby warranting further 
risk-stratification of lesions based on their progressive potential. Dynamic contrast-enhanced images, obtained 
as part of mpMRI protocol, were not used in this study due to the increasing body of evidence suggesting the 
non-inferiority of biparametric MRI for lesion  characterisation64,65. Furthermore, in this study we used Likert 
scores, which is the default system used in our department being informed by the criteria defined in PI-RADS 
v2.1. The systems are broadly similar, but Likert will often differ in scores 4 and 5 as it lacks a size threshold 
for this differentiation. The non-inferiority of Likert score assessment for the detection of clinically significant 
disease was documented  previously64,66.
In future work, we will aim to deploy a whole-gland segmentation approach, alongside habitat radiomics, to 
develop similar predictive models for use in all patients eligible for AS regardless of the presence of MR-visible 
lesions. The increased sample size will allow us to identify the best-performing machine learning technique that 
uses the optimal total number of features from each relevant feature selection approach. To assess its performance, 
we will use conventional measures of discrimination and calibration and perform decision curve analysis. A 
posteriori statistical harmonisation, such as the ComBat  method67, for explicitly dealing with the batch-effect cor-
rect in multicentric studies will be used in our future work. In such a context, automated prostate segmentation 
 approaches68,69 can accelerate the outlining time in manual segmentation procedures, as well as reduce the opera-
tor dependence for repeatable radiomic feature extraction. In addition, prostate zonal  segmentation70,71 might 
also be considered for extracting zone-specific radiomics biomarkers. Furthermore, as the intrinsic inconsistency 
of weighted images often limits the generalisability of radiomics in a multi-center context, texture analysis of 
both conventional and novel quantitative mapping techniques that have already been studied in  PCa72 is an area 
of interest. Finally, whilst this study focused on baseline prediction of PCa progression on AS, there is scope 
for improving mpMRI performance for the follow-up monitoring of AS patients. With the recently developed 
Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) scoring system including 
only subjective criteria for the assessment of radiological progression of the  disease73,74, the use of delta-radiomics 
in follow-up mpMRI scans could complement the developed baseline predictive model by acting as a quantita-
tive tool for dynamic re-evaluation of the risk of PCa progression, further increasing confidence in mpMRI as 
an alternative to repeat biopsies. In this study, we already used PRECISE 5 as an alternative to histopathological 
progression of the disease, which aligns with the global trend towards heavier reliance on MRI in navigating 
follow-up in AS and makes the results more applicable to the routine clinical practice where the two surrogates 
are used  interchangeably52,75–77.
In conclusion, a combination of clinicopathological predictors and T2WI-derived radiomic features may 
add benefit in predicting risk of PCa progression on AS. These results pave the way for larger future studies 
investigating the added value of MRI-derived radiomics to standard-of-care clinical biomarkers for improving 
baseline risk-stratification of patients suitable for enrollment on AS programmes.
Data availability
The primary research data will be made available on Mendeley Data upon the publication of this manuscript.
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